氯硝柳胺作为抗新冠病毒药物的可能作用机制。
Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19.
作者信息
Pindiprolu Sai Kiran S S, Pindiprolu Sai Harshini
机构信息
School of Pharmaceutical Sciences and Technologies, JNTUK, Kakinada, India.
Sree Sai Dental College and Research Institute, Srikakulam 532001, Andhra Pradesh, India.
出版信息
Med Hypotheses. 2020 Apr 22;140:109765. doi: 10.1016/j.mehy.2020.109765.
Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing 'old' drugs to treat 'new' diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19.
截至2020年3月25日，2019冠状病毒病（COVID-19）大流行在全球造成18440人死亡，对公众健康构成严重威胁。因此，需要有效的治疗策略来治愈这种疾病。然而，高淘汰率、高昂成本和缓慢的研发速度是新型药物研发的主要限制因素。药物再利用，即使用“老”药治疗“新”疾病，是药物研发中一种有吸引力的方法。氯硝柳胺（NIC）是一种已获批准的抗蠕虫药物，具有多种抗病毒机制。在这项研究中，我们推测了氯硝柳胺对COVID-19的潜在抗病毒机制。
Zotero 插件